Our Company
Translational Cell-Therapy Development Built on Scientific Depth
Decinova Therapeutics is advancing a focused cell-therapy and translational-development platform centered on Decidua-derived Stromal Cells (DSC). Our work brings together biological insight, manufacturing awareness, clinical-development experience and partnering capability.
Three Pillars, One Translational Foundation
How Decinova Creates Value
DSC Therapeutics — Our Flagship Platform
Decinova’s own proprietary stromal-cell platform, with a lead program in steroid-refractory acute GVHD, built on more than 15 years of translational and clinical-development experience.
Development Support for Partner Programs
Applying hands-on translational experience to support other organizations advancing their own cell-therapy programs, from preclinical strategy through clinical development.
Custom Platforms, Built and Transferred
Designing and implementing custom cell-technology platforms directly within a partner’s own facility, rather than supplying an off-the-shelf product.
What Defines Decinova
A Consistent Approach Across Every Program
Distinct Biology
A focused interest in decidua-derived stromal-cell biology and its immunomodulatory potential.
Translational Perspective
Connecting scientific rationale with manufacturing, clinical development and regulatory readiness.
Partnering Orientation
Designed to support strategic collaboration, regional development and technology transfer.
Translational Track Record
From Biology to Patients
Preclinical development, toxicology, manufacturing and clinical-administration experience spans the full path from biology to product — including historical regulatory experience such as a US IND and orphan-drug development milestones, and additional jurisdiction-specific regulatory experience.
*Figures and regulatory milestones should be accompanied by source references and appropriate jurisdiction/date context in external materials. Historical regulatory milestones must not be interpreted as current FDA or EMA marketing authorization. See Development & Regulatory History for full context.
The Development Pathway
From Biological Insight to Translation
Decinova’s own development experience — biology through characterization, manufacturing, clinical development and partnering — is the same translational pathway we bring to partner programs.
Characterization→
Manufacturing→
Clinical Development→
Partnering
A Focused Platform
Decinova’s Near-Term Corporate Focus Is DSC
Adjacent work in regenerative medicine and extracellular vesicles may inform future opportunities, while remaining secondary to the core DSC platform.
Let’s Move Cell Therapy Forward.
Tell us about your organization and the type of partnership or program you’re exploring — we’ll route it to the right conversation.